Henry James International Management Inc. boosted its position in shares of GRIFOLS S A/S (NASDAQ:GRFS) by 38.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 228,653 shares of the biotechnology company’s stock after acquiring an additional 63,109 shares during the period. GRIFOLS S A/S makes up approximately 2.1% of Henry James International Management Inc.’s holdings, making the stock its 16th largest holding. Henry James International Management Inc.’s holdings in GRIFOLS S A/S were worth $4,598,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Advisors Asset Management Inc. grew its stake in shares of GRIFOLS S A/S by 58.0% in the 4th quarter. Advisors Asset Management Inc. now owns 3,629 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 1,332 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of GRIFOLS S A/S by 45.3% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,770 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 1,799 shares during the period. SG Americas Securities LLC bought a new stake in shares of GRIFOLS S A/S in the 4th quarter valued at approximately $144,000. Amundi Pioneer Asset Management Inc. bought a new stake in shares of GRIFOLS S A/S in the 4th quarter valued at approximately $242,000. Finally, Quadrant Capital Group LLC grew its stake in shares of GRIFOLS S A/S by 20.2% in the 4th quarter. Quadrant Capital Group LLC now owns 14,098 shares of the biotechnology company’s stock valued at $252,000 after purchasing an additional 2,365 shares during the period. Hedge funds and other institutional investors own 19.96% of the company’s stock.

Several research firms have recently weighed in on GRFS. Zacks Investment Research lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Monday, April 1st. BidaskClub lowered GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 16th. Berenberg Bank lowered GRIFOLS S A/S from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Finally, Morgan Stanley lowered their price objective on GRIFOLS S A/S from $20.00 to $19.00 and set an “underweight” rating on the stock in a research note on Wednesday, January 2nd. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. GRIFOLS S A/S has a consensus rating of “Hold” and an average target price of $21.00.

NASDAQ GRFS traded down $0.24 during trading hours on Monday, reaching $18.42. 24,084 shares of the company’s stock were exchanged, compared to its average volume of 978,384. The firm has a market cap of $12.78 billion, a PE ratio of 15.74, a price-to-earnings-growth ratio of 1.33 and a beta of 1.07. GRIFOLS S A/S has a one year low of $17.42 and a one year high of $24.97. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.77 and a quick ratio of 1.22.

GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings results on Thursday, February 28th. The biotechnology company reported $0.25 EPS for the quarter. The business had revenue of $1.40 billion for the quarter. GRIFOLS S A/S had a return on equity of 16.86% and a net margin of 13.33%. As a group, equities analysts expect that GRIFOLS S A/S will post 1.28 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/henry-james-international-management-inc-raises-position-in-grifols-s-a-s-grfs/2981382.html.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

See Also: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).

Institutional Ownership by Quarter for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.